Histone Deacetylases in Prostate Cancer
Author Information
Author(s): Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche F R, Niesporek S, Denkert C, Dietel M, Kristiansen G
Primary Institution: Charité – Universitätsmedizin, Berlin, Germany
Hypothesis
The expression of class I HDACs in prostate cancer correlates with clinicopathological parameters and patient prognosis.
Conclusion
High expression levels of HDAC2 are associated with shorter PSA relapse-free survival times in prostate cancer patients.
Supporting Evidence
- HDAC1 and HDAC2 expression correlated with higher Gleason scores.
- High expression of HDAC2 was significantly associated with earlier disease relapse.
- Patients with high HDAC2 expression had a lower probability of disease-free survival.
Takeaway
This study found that certain proteins called HDACs are found in high amounts in prostate cancer, and one of them, HDAC2, can help predict how well a patient will do after treatment.
Methodology
The study used immunohistochemistry to analyze the expression of HDAC1, HDAC2, and HDAC3 in prostate cancer tissues from 192 patients.
Limitations
The study is retrospective and may not account for all variables affecting patient outcomes.
Participant Demographics
Patients aged 46–73 years, median age 62.5 years, diagnosed with prostate cancer.
Statistical Information
P-Value
p=0.002 for HDAC2 correlation with relapse-free survival
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website